Woodline Partners LP Buys 39,453 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Woodline Partners LP boosted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,015,608 shares of the company's stock after buying an additional 39,453 shares during the quarter. Woodline Partners LP owned about 2.26% of Apogee Therapeutics worth $46,007,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Barclays PLC increased its position in Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company's stock worth $21,443,000 after buying an additional 287,243 shares during the last quarter. Swiss National Bank increased its position in Apogee Therapeutics by 17.5% during the fourth quarter. Swiss National Bank now owns 44,300 shares of the company's stock worth $2,007,000 after buying an additional 6,600 shares during the last quarter. SG Americas Securities LLC increased its position in Apogee Therapeutics by 22.2% during the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock worth $448,000 after buying an additional 1,796 shares during the last quarter. JPMorgan Chase & Co. increased its position in Apogee Therapeutics by 26.1% during the fourth quarter. JPMorgan Chase & Co. now owns 37,255 shares of the company's stock worth $1,688,000 after buying an additional 7,700 shares during the last quarter. Finally, Northern Trust Corp increased its position in Apogee Therapeutics by 6.8% during the fourth quarter. Northern Trust Corp now owns 327,292 shares of the company's stock worth $14,826,000 after buying an additional 20,743 shares during the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Stock Up 0.4%

APGE stock traded up $0.18 during mid-day trading on Thursday, reaching $40.36. 247,406 shares of the stock traded hands, compared to its average volume of 523,922. Apogee Therapeutics, Inc. has a 52 week low of $26.20 and a 52 week high of $63.50. The business has a 50-day moving average of $36.73 and a two-hundred day moving average of $40.79. The firm has a market capitalization of $1.86 billion, a PE ratio of -16.68 and a beta of 1.70.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.24. On average, equities research analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 2,725 shares of the stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $35.75, for a total value of $97,418.75. Following the completion of the sale, the insider now owns 244,448 shares in the company, valued at approximately $8,739,016. This trade represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. The trade was a 0.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,175 shares of company stock worth $587,191. Company insiders own 42.77% of the company's stock.

Analyst Ratings Changes

APGE has been the topic of several analyst reports. Citigroup initiated coverage on shares of Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 target price on the stock. Wedbush restated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Finally, Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has an average rating of "Buy" and an average target price of $94.60.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.